Granted Patent
B2
US 12,193,731 · App. 18/144,368 · Granted Jan 14, 2025
Chemical ablation formulations and methods of treatments for various diseases
Assignee:
Neurotronic, Inc.
A61B18/1492A61B18/0218A61B18/18A61B18/1815A61B18/24A61K49/0438A61M25/10A61N7/00A61B2018/00285A61B2018/00345A61B2018/00482A61B2018/00541A61B2018/00577A61B2018/00994A61B2018/0212A61F2007/0063A61F2007/0091A61F2007/126A61K47/10A61K47/12A61K47/14A61M25/1011A61M2025/1052A61N2007/0043
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and/or energy are effective to injury or damage the tissues to have a benefit of symptom relive.
Claims (28)
1. A method of treating diseases comprising hypertension and diabetes, the method comprising:
inserting a delivery catheter into a vascular lumen adjacent to a nerve;
delivering energy from the delivery catheter adjacent to the nerve, wherein the energy is chosen from radiofrequency, cryoablation, microwave, laser, ultrasound, high intensity focused ultrasound, and combinations thereof;
infusing a chemical formulation at a temperature and at a pressure from the delivery catheter adjacent to the nerve, wherein the chemical formulation is at least one of 10 wt % to 100 wt % ethanol and 1 wt % to 100 wt % acetic acid, wherein an amount of the chemical formulation delivered in combination with the amount of energy delivered is effective to injure or damage the nerve to have a benefit of relieving symptoms of the diseases; and
withdrawing the delivery catheter from the body lumen;
wherein the diseases comprise hypertension and diabetes.
2. The method of claim 1 , wherein the diseases further comprise obesity.
3. The method of claim 1 , wherein the diseases further comprise heart failure.
4. The method of claim 1 , wherein the diseases further comprise pulmonary arterial hypertension.
5. The method of claim 1 , wherein the vascular lumen comprises a renal artery.
6. The method of claim 1 , wherein the method is performed with the vascular lumen comprising a renal artery and is performed again with the vascular lumen comprising a different vascular lumen.
7. The method of claim 1 , wherein the energy delivered adjacent to the nerve is sufficient to bring the temperature adjacent to the nerve to a range of −40° C. to 140° C., and/or wherein the energy delivered from a chemical formulation adjacent to the nerve is in an amount from about 2 cal/g to about 150 cal/g.
8. The method of claim 1 , wherein the delivery catheter is a needle-based delivery catheter.
9. The method of claim 1 , wherein the delivery catheter is a balloon delivery catheter comprising a balloon disposed along an elongated shaft, wherein the method further comprises:
inflating the balloon after inserting and before the delivering of the energy and chemical formulation; and
deflating the balloon after the delivering of the energy and chemical formulation and before the withdrawing.
10. The method of claim 9 , wherein the balloon has a diameter in an inflated state in a range of from 2 millimeters to 30 millimeters.
11. The method of claim 9 , wherein the balloon delivery catheter further comprises a marker band located distally of the balloon.
12. The method of claim 9 , wherein the balloon comprises a material chosen from a polyamide, a nylon, a polyether block amide, a polyester, a polyethylene terephthalate, a polyurethane, a copolymer thereof, and a mixture thereof.
13. The method of claim 1 , wherein the chemical formulation comprises at least one of a gas, vapor, liquid, solution, and an emulsion and/or suspension of one or more ingredients.
14. The method of claim 1 , wherein the temperature of the chemical formulation is in the range of −40° C. to 140° C., and wherein the pressure of the formulation is in the range of 1 to 12 ATM.
15. The method of claim 1 , wherein infusion of the chemical formulation from the delivery catheter adjacent to the nerve is effective to decrease the temperature of the vascular lumen adjacent to the nerve.
16. A method of treating diseases comprising hypertension and diabetes, the method comprising:
inserting a delivery catheter into a vascular lumen adjacent to a nerve;
delivering energy from the delivery catheter adjacent to the nerve, wherein the energy is chosen from radiofrequency, cryoablation, microwave, laser, ultrasound, high intensity focused ultrasound, and combinations thereof;
infusing a chemical formulation at a temperature and at a pressure from the delivery catheter adjacent to the nerve, wherein the chemical formulation is 100 wt % ethanol, wherein an amount of the chemical formulation delivered in combination with the amount of energy delivered is effective to injure or damage the nerve to have a benefit of relieving symptoms of the diseases; and
withdrawing the delivery catheter from the body lumen;
wherein the diseases comprise hypertension and diabetes.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 9, 2023
From: WANG, LIXIAO
To: NEUROTRONIC, INC.
Reel/Frame 063573/0394 →
Continuity (8)
Continuation
14438411
Provisional Application
61849928
· Feb 5, 2013
Provisional Application
61848483
· Jan 4, 2013
Provisional Application
61797647
· Dec 12, 2012
Provisional Application
61796118
· Nov 2, 2012
References Cited (350)
US 4254056A
· Konno
· 1981
[cited by examiner]
US 4573966A
· Weikl et al.
· 1986
[cited by applicant]
US 4653438A
· Russell
· 1987
[cited by applicant]
US 5045061A
· Seifert et al.
· 1991
[cited by applicant]
US 5263931A
· Miller
· 1993
[cited by applicant]
US 5314443A
· Rudnick
· 1994
[cited by applicant]
US 5315992A
· Dalton
· 1994
[cited by applicant]
US 5380284A
· Don
· 1995
[cited by applicant]
US 5419763A
· Hildebrand
· 1995
[cited by applicant]
US 5423755A
· Kesten et al.
· 1995
[cited by applicant]
US 5460610A
· Don
· 1995
[cited by applicant]
US 5599307A
· Bacher et al.
· 1997
[cited by applicant]
US 5681281A
· Vigil et al.
· 1997
[cited by applicant]
US 5720735A
· Dorros
· 1998
[cited by applicant]
US 6048332A
· Duffy et al.
· 2000
[cited by applicant]
US 6062223A
· Palazzo et al.
· 2000
[cited by applicant]
US 6135981A
· Dyke
· 2000
[cited by applicant]
US 6148222A
· Ramsey, III
· 2000
[cited by applicant]
US 6217554B1
· Green
· 2001
[cited by applicant]
US 6258087B1
· Edwards et al.
· 2001
[cited by applicant]
US 6623452B2
· Chien et al.
· 2003
[cited by applicant]
US 6685672B1
· Forman
· 2004
[cited by applicant]
US 7617005B2
· Demarais et al.
· 2009
[cited by applicant]
US 7653438B2
· Deem et al.
· 2010
[cited by applicant]
US 7717948B2
· Demarais et al.
· 2010
[cited by applicant]
US 8052668B2
· Sih
· 2011
[cited by applicant]
US 8372054B2
· Duffy et al.
· 2013
[cited by applicant]
US 8740849B1
· Fischell et al.
· 2014
[cited by applicant]
US 8774913B2
· Demarais et al.
· 2014
[cited by applicant]
US 8840601B2
· Salahieh et al.
· 2014
[cited by applicant]
US 9114123B2
· Vafai et al.
· 2015
[cited by applicant]
US 20020014238A1
· Kotmel
· 2002
[cited by applicant]
US 20020177846A1
· Mulier
· 2002
[cited by applicant]
US 20030066532A1
· Gobel
· 2003
[cited by applicant]
US 20050288639A1
· Hibner
· 2005
[cited by applicant]
US 20090192505A1
· Askew
· 2009
[cited by examiner]
US 20100087781A1
· Adams et al.
· 2010
[cited by applicant]
US 20120116438A1
· Salahieh et al.
· 2012
[cited by applicant]
US 20120209251A1
· Bates
· 2012
[cited by applicant]
US 20120215212A1
· Selzer et al.
· 2012
[cited by applicant]
US 20120259269A1
· Meyer
· 2012
[cited by applicant]
US 20130053792A1
· Fischell et al.
· 2013
[cited by applicant]
US 20130138082A1
· Salahieh et al.
· 2013
[cited by applicant]
US 20150272666A1
· Wang
· 2015
[cited by applicant]
US 20190076186A1
· Fischell et al.
· 2019
[cited by applicant]
US 20200086093A1
· Wang
· 2020
[cited by applicant]
US 20210275784A1
· Wang
· 2021
[cited by applicant]
US 20210275785A1
· Wang
· 2021
[cited by applicant]
US 20210275786A1
· Wang
· 2021
[cited by applicant]
US 20210275787A1
· Wang
· 2021
[cited by applicant]
US 20220233238A1
· Wang et al.
· 2022
[cited by applicant]
US 20220233827A1
· Wang et al.
· 2022
[cited by applicant]
CN 1593359A
· 2005
[cited by applicant]
CN 101035593A
· 2007
[cited by applicant]
CN 101861184A
· 2010
[cited by applicant]
CN 102481428A
· 2012
[cited by applicant]
CN 102573466A
· 2012
[cited by applicant]
CN 102600546A
· 2012
[cited by applicant]
CN 102698354A
· 2012
[cited by applicant]
CN 102727986A
· 2012
[cited by applicant]
CN 102743163A
· 2012
[cited by applicant]
CN 107106820A
· 2017
[cited by applicant]
CN 110772311A
· 2020
[cited by applicant]
CN 113040895A
· 2021
[cited by applicant]
CN 114025826A
· 2022
[cited by applicant]
EP 2497524A1
· 2012
[cited by applicant]
EP 2914326
· 2023
[cited by applicant]
JP S5769814
· 1982
[cited by applicant]
JP H04215767A
· 1992
[cited by applicant]
JP H07308382A
· 1995
[cited by applicant]
JP 08508917A
· 1996
[cited by applicant]
JP 2000279524A
· 2000
[cited by applicant]
JP 2004035128
· 2004
[cited by applicant]
JP 2004180892A
· 2004
[cited by applicant]
JP 2004528924A
· 2004
[cited by applicant]
JP 2005506101A
· 2005
[cited by applicant]
JP 2006502801A
· 2006
[cited by applicant]
JP 2010078379A
· 2010
[cited by applicant]
JP 2010519005A
· 2010
[cited by applicant]
JP 2010528815A
· 2010
[cited by applicant]
JP 2011519699A
· 2011
[cited by applicant]
JP 2012505050A
· 2012
[cited by applicant]
JP 2012508067A
· 2012
[cited by applicant]
JP 2012517858A
· 2012
[cited by applicant]
JP 2012524808A
· 2012
[cited by applicant]
JP 2013517847A
· 2013
[cited by applicant]
JP 2014524342A
· 2014
[cited by applicant]
JP 2014527272A
· 2014
[cited by applicant]
JP 2015536945A
· 2015
[cited by applicant]
JP 2017533036A
· 2017
[cited by applicant]
JP 6389185B2
· 2018
[cited by applicant]
JP 2018153239
· 2018
[cited by applicant]
JP 2020189858A
· 2020
[cited by applicant]
JP 2021046397A
· 2021
[cited by applicant]
JP 2022538239a
· 2022
[cited by applicant]
JP 2023027052A
· 2023
[cited by applicant]
WO WO9421320A1
· 1994
[cited by applicant]
WO WO9618427A1
· 1996
[cited by applicant]
WO WO9717099A1
· 1997
[cited by applicant]
WO WO0119445A1
· 2001
[cited by applicant]
WO WO02051490A1
· 2002
[cited by applicant]
WO WO2006055695A1
· 2006
[cited by applicant]
WO WO2008106357A1
· 2008
[cited by applicant]
WO WO2009076732A1
· 2009
[cited by applicant]
WO WO2009082433A2
· 2009
[cited by applicant]
WO WO2010033686A1
· 2010
[cited by applicant]
WO WO2010124120A1
· 2010
[cited by applicant]
WO WO2011094367A1
· 2011
[cited by applicant]
WO WO2011119159A1
· 2011
[cited by applicant]
WO WO2013026565A1
· 2013
[cited by applicant]
WO WO2013028781A1
· 2013
[cited by applicant]
WO WO2013067382A1
· 2013
[cited by applicant]
WO WO2013090848A1
· 2013
[cited by applicant]
WO WO2014070820A2
· 2014
[cited by applicant]
WO WO2015058296A1
· 2015
[cited by applicant]
WO WO2016070032A1
· 2016
[cited by applicant]
WO WO2020264152A1
· 2020
[cited by applicant]
WO 2023091475
· 2023
[cited by applicant]
“U.S. Appl. No. 14/438,411, Advisory Action mailed Apr. 30, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed Feb. 25, 2019”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Final Office Action mailed May 9, 2018”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Sep. 21, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Non Final Office Action mailed Oct. 20, 2017”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Preliminary Amendment filed Jul. 28, 2015”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Jan. 17, 2018 to Non Final Office Action mailed Oct. 20, 2017”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Apr. 16, 2019 to Final Office Action mailed Feb. 25, 2019”, 18 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 7, 2018 to Final Office Action mailed May 9, 2018”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Aug. 25, 2017 to Restriction Requirement mailed Jul. 14, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Response filed Oct. 8, 2018 to Non Final Office Action mailed Sep. 21, 2018”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 14/438,411, Restriction Requirement mailed Jul. 14, 2017”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Advisory Action mailed Jul. 30, 2019”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Corrected Notice of Allowability mailed Nov. 20, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed May 3, 2019”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Final Office Action mailed Aug. 16, 2018”, 26 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Feb. 15, 2018”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Non Final Office Action mailed Nov. 30, 2018”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Notice of Allowance mailed Oct. 1, 2019”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Preliminary Amendment filed Apr. 20, 2016”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Mar. 20, 2019 to Non Final Office Action mailed Nov. 30, 2018”, 17 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jun. 14, 2018 to Non Final Office Action mailed Feb. 15, 2018”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Jul. 1, 2019 to Final Office Action mailed May 3, 2019”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Oct. 26, 2018 to Final Office Action mailed Aug. 16, 2018”, 20 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Response filed Dec. 27, 2017 to Restriction Requirement mailed Oct. 31, 2017”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/133,976, Restriction Requirement mailed Oct. 31, 2017”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Examiner Interview Summary mailed Jun. 4, 2018”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Final Office Action mailed Jan. 15, 2019”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed May 18, 2018”, 21 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Non Final Office Action mailed Sep. 14, 2018”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Notice of Allowance mailed Mar. 27, 2019”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Preliminary Amendment filed Apr. 26, 2017”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Mar. 14, 2019 to Final Office Action mailed Jan. 15, 2019”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 15/521,973, Response filed Dec. 10, 2018 to Non Final Office Action mailed Sep. 14, 2018”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/156,163, Non Final Office Action mailed Apr. 2, 2020”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/156,163, Notice of Allowance mailed Jul. 22, 2020”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 16/156,163, Response filed Jul. 1, 2020 to Non Final Office Action mailed Apr. 2, 2020”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Corrected Notice of Allowability mailed Apr. 27, 2022”, 5 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Final Office Action mailed Feb. 24, 2022”, 18 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Non Final Office Action mailed Oct. 5, 2021”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Notice of Allowance mailed Apr. 11, 2022”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Preliminary Amendment filed Jul. 9, 2019”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Mar. 9, 2022 to Final Office Action mailed Feb. 24, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/419,587, Response filed Nov. 4, 2021 to Non Final Office Action mailed Oct. 5, 2021”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,192, Non Final Office Action mailed Nov. 30, 2022”, 21 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,192, Notice of Allowance mailed Mar. 8, 2023”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,192, Response filed Feb. 9, 2023 to Non Final Office Action mailed Nov. 30, 2022”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Non Final Office Action mailed Sep. 15, 2022”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowability mailed Mar. 1, 2023”, 4 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Notice of Allowance mailed Feb. 3, 2023”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,213, Response filed Dec. 13, 2022 to Non Final Office Action mailed Sep. 15, 2022”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed May 12, 2022”, 16 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Non Final Office Action mailed Sep. 30, 2021”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Feb. 11, 2022”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Notice of Allowance mailed Aug. 26, 2022”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Aug. 11, 2022 to Non Final Office Action mailed May 12, 2022”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 16/563,235, Response filed Nov. 16, 2021 to Non Final Office Action mailed Sep. 30, 2021”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed Jul. 26, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Feb. 6, 2023”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Apr. 5, 2022”, 23 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Apr. 18, 2023 to Non Final Office Action mailed Feb. 6, 2023”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 5, 2022 to Non Final Office Action mailed Apr. 5, 2022”, 19 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Oct. 26, 2022 to Final Office Action mailed Jul. 26, 2022”, 12 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Apr. 19, 2023 to Restriction Requirement mailed Mar. 2, 2023”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Restriction Requirement mailed Mar. 2, 2023”, 7 pgs.
[cited by applicant]
“Chinese Application Serial No. 202080046425.X, Voluntary Amendment filed Jun. 14, 2022”, w/ English Claims, 12 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Jan. 17, 2018”, (English Translation), 8 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Feb. 19, 2019”, W/ English Translation, 6 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed May 19, 2017”, w/ English Translation, 18 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Office Action mailed Dec. 27, 2019”, w/ English translation, 12 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Apr. 2, 2018 to Office Action mailed Jan. 17, 2018”, w/ English claims, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Aug. 23, 2019 to Office Action mailed Feb. 19, 2019”, w/English Claims, 14 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Oct. 9, 2017 to Office Action mailed May 19, 2017”, w/ English Claims, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 201380055918.X, Response filed Nov. 27, 2018 to Office Action mailed”, w/English Claims, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Jul. 2, 2020”, w/ English translation, 14 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Office Action mailed Sep. 3, 2019”, W/English Translation, 17 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Mar. 18, 2020 to Office Action mailed Sep. 3, 2019”, w/English Claims, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Response filed Nov. 24, 2020 to Office Action mailed Jul. 2, 2020”, w/English Claims, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 201580058938.1, Voluntary Amendment mailed Feb. 22, 2018”, w/ English Claims, 21 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Decision of Rejection mailed Mar. 14, 2023”, w/ English translation, 13 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed May 20, 2022”, w/ English translation, 16 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Office Action mailed Oct. 18, 2022”, w/ English translation, 7 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Feb. 27, 2023 to Office Action mailed Oct. 18, 2022”, w/ English Claims, 8 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Sep. 28, 2022 to Office Action mailed May 20, 2022”, w/ English Claims, 7 pgs.
[cited by applicant]
“Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma”, A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial Am J Respir Crit Care Med vol. 181., (2010), 9 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 7 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Communication Pursuant to Article 94(3) EPC mailed Jun. 1, 2018”, 9 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Extended European Search Report mailed Jun. 6, 2016”, 6 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Invitation pursuant to Article 94(3) and Rule 71(1) EPC mailed Oct. 11, 2022”, 4 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Office Action mailed Jun. 12, 2015”, 3 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Jul. 20, 2020 to Communication Pursuant to Article 94(3) EPC mailed Mar. 20, 2020”, 13 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Aug. 10, 2022 to Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 52 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Oct. 19, 2015 to Office Action mailed Jun. 12, 2015”, 13 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Response filed Dec. 1, 2016 to Extended European Search Report mailed Jun. 6, 2016”, 20 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Jan. 28, 2022”, 10 pgs.
[cited by applicant]
“European Application Serial No. 13851462.5, Summons to Attend Oral Proceedings mailed Feb. 28, 2022”, 4 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 10 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 8 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Extended European Search Report mailed May 30, 2018”, 15 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Reponse filed Nov. 12, 2018 to Extended European Search Report mailed May 30, 2018”, 17 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Response filed Sep. 2, 2022 to Communication Pursuant to Article 94(3) EPC mailed Apr. 28, 2022”, 116 pgs.
[cited by applicant]
“European Application Serial No. 15853911.4, Response filed Oct. 27, 2020 to Communication Pursuant to Article 94(3) EPC mailed Apr. 30, 2020”, 14 pgs.
[cited by applicant]
“European Application Serial No. 20832727.0, Extended European Search Report mailed Feb. 28, 2023”, 9 pgs.
[cited by applicant]
“European Application Serial No. 20832727.0, Response to Communication pursuant to Rules 161 and 162 filed Aug. 19, 2022”, 13 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Preliminary Report on Patentability mailed May 11, 2017”, 9 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2015/058296, International Search Report mailed Jan. 21, 2016”, 2 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2015/058296, Written Opinion mailed Jan. 21, 2016”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2020/039605, International Preliminary Report on Patentability mailed Jan. 6, 2022”, 9 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2020/039605, International Search Report mailed Sep. 28, 2020”, 2 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2020/039605, Written Opinion mailed Sep. 28, 2020”, 7 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2022/050087, International Search Report mailed Mar. 1, 2023”, 3 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2022/050087, Written Opinion mailed Mar. 1, 2023”, 4 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Jul. 4, 2017”, w/English Translation, 12 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Office Action mailed Dec. 29, 2017”, With English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Mar. 16, 2018 to Office Action mailed Dec. 29, 2017”, w/ English Claims, 11 pgs.
[cited by applicant]
“Japanese Application Serial No. 2015-540733, Response filed Oct. 4, 2017 to Office Action mailed Jul. 4, 2017”, w/ English Claims, 19 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Refusal mailed Jul. 6, 2021”, w/ English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/ English Translation, 13 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Office Action mailed Jun. 23, 2020”, w/ English translation, 14 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Mar. 6, 2020 to Notification of Reasons for Rejection mailed Sep. 10, 2019”, w/English Claims, 14 pgs.
[cited by applicant]
“Japanese Application Serial No. 2017-523517, Response filed Oct. 23, 2020 to Office Action mailed Jun. 23, 2020”, w/English Claims, 14 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Examiners Decision of Final Refusal mailed Apr. 7, 2020”, w/ English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w/ English Translation, 17 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Jul. 2, 2019”, W/ English Translation, 16 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Notification of Reasons for Refusal mailed Aug. 17, 2021”, w/ English Translation, 17 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Office Action mailed Nov. 8, 2022”, w/ English Translation, 45 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w/ English Claims, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Oct. 1, 2019 to Notification of Reasons for Refusal mailed Jul. 2, 2019”, w/English Claims, 10 pgs.
[cited by applicant]
“Japanese Application Serial No. 2018-153239, Response filed Nov. 16, 2021 to Notification of Reasons for Refusal mailed Aug. 17, 2021”, w/Engilsh Claims, 10 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-134047, Examiners Decision of Final Refusal mailed Jun. 21, 2022”, w/ English translation, 6 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-134047, Notification of Reasons for Refusal mailed Sep. 28, 2021”, w/ English Translation, 16 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-134047, Response filed Mar. 28, 2022 to Notification of Reasons for Refusal mailed Sep. 28, 2021”, w/ English translation, 21 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Refusal mailed Jan. 5, 2022”, w/ English Translation, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Office Action mailed Nov. 22, 2022”, w/o English Translation, 1 pg.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Preliminary Examination Report mailed Jan. 24, 2023”, w/ English Translation, 2 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Response field Dec. 21, 2022 to Office Action mailed Nov. 22, 2022”, w/English Translation, 11 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Apr. 5, 2022 to Notification of Reasons for Refusal mailed Jan. 5, 2022”, w English translation, 6 pgs.
[cited by applicant]
“Japanese Application Serial No. 202080044525.9, Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w/ English Translation, 8 pgs.
[cited by applicant]
“Japanese Application Serial No. 202080044525.9, Response filed Nov. 7, 2022 to Examiners Decision of Final Refusal mailed Jul. 5, 2022”, w/ English Claims, 13 pgs.
[cited by applicant]
Dunican, Eleanor M, “Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction”, J Clin Invest. 2018;128(3), (2018), 14 pgs.
[cited by applicant]
Greer, M, et al., “Paclitaxel-Coated Balloons in Refractory Nonanastomostic Airway Stenosis Following Lung Transplantation”, American Journal of Transplantation 2014 14: 2400-2405, (2014), 2400-2405.
[cited by applicant]
Kim, K. C., et al., “Airway goblet cell mucin: its structure and regulation of secretion”, Series Airway Mucus Eur Respir J 1997; 10:, (1997), pp. 2644-2649.
[cited by applicant]
Krmisky, William, et al., “Thermal ablation for asthma: current status and technique”, J Thorac Dis 2017;9(Suppl 2):S104-S109, (2017), 6 pgs.
[cited by applicant]
Krum, H., et al., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.”, Lancet, 373(9671), (2009), 2375- 1281.
[cited by applicant]
Menzella, Francesco, et al., “Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights”, Journal of Asthma and Allergy 2020:13, (2020), 13 pgs.
[cited by applicant]
Peters, Michael C, et al., “Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency”, Am J Respir Crit Care Med vol. 202, Iss 7, (2020), 10 pgs.
[cited by applicant]
Sakata, Kenneth K, et al., “Paclitaxel-coated balloon dilation for central airway obstruction”, Respiratory Medicine Case Reports 24, (2018), 129-132.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Nov. 11, 2023”, w English Translation, 10 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Dec. 22, 2023”, w English Translation, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Jan. 25, 2024 to Final Office Action mailed Nov. 1, 2023”, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Final Office Action mailed May 15, 2023”, 26 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Voluntary Amendment filed Jun. 19, 2023”, 15 pgs.
[cited by applicant]
“Chinese Application Serial No. 201910917938.2, Response filed Jun. 28, 2023 to Decision of Rejection mailed Mar. 14, 2023”, w English Claims, 13 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Response filed Jul. 13, 2023 to Final Office Action mailed May 15, 2023”, 19 pgs.
[cited by applicant]
“European Application Serial No. 23183741.0, Extended European Search Report mailed Jul. 21, 2023”, 14 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Response filed Aug. 9, 2023 to Non Final Office Action mailed May 31, 2023”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Advisory Action mailed Jul. 26, 2023”, 3 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Non Final Office Action mailed May 31, 2023”, 13 pgs.
[cited by applicant]
Tian, Juanhua, “Rectifying disorder of extracellularmatrix to suppress urethral stricture by protein nanofilm-controlled drug delivery from urinary catheter”, nature communications, (May 17, 2023), 17 pgs.
[cited by applicant]
“U.S. Appl. No. 16/690,992, Non Final Office Action mailed Aug. 24, 2023”, 23 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,765, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,795, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,823, Restriction Requirement mailed Sep. 13, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 17/329,842, Restriction Requirement mailed Oct. 17, 2023”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Final Office Action mailed Nov. 1, 2023”, 16 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Notification of Reasons for Rejection mailed Oct. 31, 2023”, W English Translation, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 16/986,717, Notice of Allowance mailed Feb. 14, 2024”, 8 pgs.
[cited by applicant]
“U.S. Appl. No. 17/010,271, Response filed Jun. 12, 2024 to Restriction Requirement mailed May 22, 2024”, 9 pgs.
[cited by applicant]
“U.S. Appl. No. 17/010,271, Restriction Requirement mailed May 22, 2024”, 7 pgs.
[cited by applicant]
“U.S. Appl. No. 18/295,961, Non Final Office Action mailed Jun. 21, 2024”, 17 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Response filed May 6, 2024 to Office Action mailed Dec. 22, 2023”, w/ current English claims, 15 pgs.
[cited by applicant]
“European Application Serial No. 23183741.0, Response filed Feb. 19, 2024 to Extended European Search Report mailed Jul. 21, 2023”, 12 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2022/050087, International Preliminary Report on Patentability mailed May 30, 2024”, 6 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Notification of Reasons for Rejection mailed May 14, 2024”, W/English Translation, 25 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Examiners Decision of Final Refusal mailed May 14, 2024”, W/English Translation, 4 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-169101, Response filed Jan. 30, 2024 to Notification of Reasons for Rejection mailed Oct. 31, 2023”, w/ English Claims, 14 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Notification of Reasons for Refusal mailed Jun. 4, 2024”, w/ English translation, 6 pgs.
[cited by applicant]
“Japanese Application Serial No. 2022-178135, Response filed Feb. 27, 2024 to Notification of Reasons for Refusal mailed Nov. 11, 2023”, w/ english claims, 9 pgs.
[cited by applicant]
“Recording of clinical analysis research association”, w/English translation No. 5, [Online] Retrieved from the internet: <http://www.jrsca.jp/contents/records/contents/PDF/5-PDF?>, (Feb. 2005), 7 pgs.
[cited by applicant]
Sugimoto, Ayurni, et al., “Nervous Control of Glucose Metabolism in the Liver”, W/English translation Lifestyle Research vol. 3, No. 1, 138-141, (2001), 10 pgs.
[cited by applicant]
“Chinese Application Serial No. 202110227749.X, Office Action mailed Jul. 10, 2024”, w English Translation, 9 pgs.
[cited by applicant]
“Japanese Application Serial No. 2020-178075, Response filed Aug. 13, 2024 to Notification of Reasons for Rejection mailed May 14, 2024”, W English Claims, 9 pgs.
[cited by applicant]
Cited By (4)